



University of Dundee

The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC)

Chalmers, James D.; Crichton, Megan L.; Goeminne, Pieter C.; Loebinger, Michael R.; Haworth, Charles; Almagro, Marta; Vendrell, Montse; De Soyza, Anthony; Dhar, Raja; Morgan, Lucy; Blasi, Francesco; Aliberti, Stefano; Boyd, Jeanette; Polverino, Eva; on behalf of EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group

Published in:
Breathe

DOI:
[10.1183/20734735.005117](https://doi.org/10.1183/20734735.005117)

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Chalmers, J. D., Crichton, M. L., Goeminne, P. C., Loebinger, M. R., Haworth, C., Almagro, M., ... on behalf of EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group (2017). The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. *Breathe*, 13(3), 180-192. DOI: 10.1183/20734735.005117

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.



Credit: Sashkin, shutterstock.com

Educational aims

- To understand the role of Clinical Research Collaborations as the major way in which the European Respiratory Society can stimulate clinical research in different disease areas
- To understand some of the key features of successful disease registries
- To review key epidemiological, clinical and translational studies of bronchiectasis contributed by the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) project in the past 5 years
- To understand the key research priorities identified by EMBARC for the next 5 years



James D. Chalmers¹, Megan Crichton¹, Pieter C. Goeminne², Michael R. Loebinger³, Charles Haworth⁴, Marta Almagro⁵, Montse Vendrell⁶, Anthony De Souza⁷, Raja Dhar⁸, Lucy Morgan⁹, Francesco Blasi¹⁰, Stefano Aliberti¹⁰, Jeanette Boyd¹¹, Eva Polverino¹² on behalf of EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group



jchalmers@dundee.ac.uk



@EMBARCnetwork



<https://www.linkedin.com/company/embarc-the-european-bronchiectasis-register>



¹Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. ²AZ Nikolaas, Sint-Niklaas, Belgium. ³Royal Brompton Hospital, London, UK. ⁴Papworth Hospital, Cambridge, UK. ⁵EMBARC/ELF Patient Advisory Group. ⁶Bronchiectasis Research Group, Dr Trueta University Hospital, Girona, Spain. ⁷Freeman Hospital, Newcastle, UK. ⁸Dept of Respiratory Medicine, Fortis Hospital, Kolkata, India. ⁹Dept of Respiratory Medicine, Concord Hospital, Concord Clinical School, University of Sydney, Sydney, Australia. ¹⁰Dept of Pathophysiology and Transplantation, University of Milan, Cardio-Thoracic Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. ¹¹European Lung Foundation, Sheffield, UK. ¹²Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron, Barcelona, Spain.

The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration

In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and rare diseases such as cystic fibrosis, there has been little research and few clinical trials in bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging because of the heterogeneous nature of the disease.

In an effort to address decades of underinvestment in bronchiectasis research, education and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative pan-European network to bring together bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 as a Clinical Research Collaboration, providing support and infrastructure to allow the project to grow.

EMBARC has now established an international bronchiectasis registry that is active in more than 30 countries both within and outside Europe. Beyond the registry, the network participates in designing and facilitating clinical trials, has set international research priorities, promotes education and has participated in producing the first international bronchiectasis guidelines. This manuscript article the development, structure and achievements of EMBARC from 2012 to 2017.



@ERSpublications

Learn about @EMBARCnetwork, a successful @ERStalk Clinical Research Collaboration with @EuropeanLung <http://ow.ly/IOI230drGf1>

Cite as: Chalmers JD, Crichton M, Goeminne PC, *et al.* The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. *Breathe* 2017; 13: 180–192.

Patients with bronchiectasis typically suffer from cough, sputum production, frequent chest infections and a number of other symptoms on a daily basis [1, 2]. In addition, patients have to

struggle with the uncertainty provoked by frequent, unpredictable disease exacerbations [3, 4]. On top of the physical symptoms, patients have to deal with a diagnostic delay that is not infrequently more than



© ERS 2017

a decade, and many patients are acutely aware that primary care physicians and nonspecialists know little about their condition, and that the evidence base for treatment is poor [5, 6].

Bronchiectasis has been described as an orphan disease but while the European Union (EU) defines an orphan or rare disease as one affecting fewer than one in 2000 people, the latest estimates suggest that bronchiectasis is relatively common [7–10]. Most recent estimates place the true prevalence at one in 206 for men and one in 176 for women in the UK, one in 276 persons in Catalonia (Spain), and one in 1492 persons in Germany [7–10]. Bronchiectasis is therefore not an orphan disease in the true sense of prevalence but has the characteristics of an orphan disease in terms of a weak evidence base, a lack of attention from scientists, clinicians, regulators and funders, and an absence of high-quality randomised controlled trials [11–13].

Although guidelines on the management of cough from CHEST in the USA in 2006 may be regarded as one of the first guidelines for bronchiectasis, the first guidelines to attempt to cover the totality of investigation and management of bronchiectasis worldwide were the Spanish (SEPAR) guidelines published in 2008 and subsequently the British Thoracic Society Guidelines in 2010 [12, 14, 15]. A reflection of poor state of evidence at that time is the fact that only three recommendations in the ≥200-page British Thoracic Society document were given a grade A recommendation, meaning the authors had a high degree of confidence in the recommendation [12]. These were to screen for antibody deficiency by measuring immunoglobulins, to offer physiotherapy exercises such as the active cycle of breathing technique and that recombinant DNase should

not be used for treatment [12, 16]. The majority of treatment recommendations were given a Grade D recommendation indicating expert opinion in the absence of robust evidence [12].

Europe has contributed a substantial majority of the published data on bronchiectasis over the past 20 years. A systematic review by ALIBERTI *et al.* [17] (2000–2015) showed that even within Europe, the majority of published studies were from the UK, with further contribution from Spain, Italy and other Western European countries but with a paucity of published data from Eastern Europe (figure 1). Collaborative studies involving data from more than one European country could not be identified prior to 2014.

The backdrop to the development of the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) project was therefore a common and disabling chronic disease, a limited research and evidence base, a hostile funding environment, and an absence of pan-European cooperation and coordination.

What is EMBARC?

EMBARC was established in 2012 as a collaborative group within European Respiratory Society (ERS) Assembly 10 (Respiratory Infections) with the objective of creating a European bronchiectasis registry, harmonising existing databases, and identifying opportunities to raise the profile of bronchiectasis at ERS and EU levels [18, 19].

In 2013, EMBARC applied to become an ERS Clinical Research Collaboration (CRC). ERS contributes to the coordination of activities in respiratory medicine across Europe by funding CRCs, which are designed as pan-European networks aiming to create a critical mass of research expertise to improve clinical research within a specific disease area [20]. EMBARC was one of the first ERS CRCs to be funded (in 2013, with funding running from 2014 to 2017). The portfolio of CRCs is now highly diverse, covering disease areas from sleep apnoea, intensive care unit-related respiratory infections, childhood and adult interstitial lung diseases, severe asthma, and pulmonary function [20, 21].

CRCs stimulate research in a number of ways. In addition to funding, they provide access to the considerable resources of the ERS, providing access to ERS members, national delegates and national societies through the Forum of International Respiratory Societies (FIRS) (<https://www.firsnet.org/news-and-actions>). They provide the ability to hold meetings and symposia at the ERS International Congress and, perhaps most importantly in the case of EMBARC, they provide an identity and mark of approval to the network, which enables the network to recruit both funders and participants through the trust that individual healthcare professionals, patients and funders have in the ERS [20, 21].




Figure 1 Published original research studies in 2000–2015 on adult bronchiectasis worldwide (excluding cystic fibrosis).

EMBARC was approved as an ERS CRC in 2013, chaired by J.D. Chalmers from the University of Dundee (Dundee, UK) and E. Polverino from the University of Barcelona (Barcelona, Spain), with the collaboration offices based at the University of Dundee.

Setting up an international registry

The primary objective of the EMBARC CRC was the creation of a pan-European, prospective registry of patients with bronchiectasis [18]. No pan-European registries for bronchiectasis existed prior to 2015, with only a small number of countries or individual regions within countries having registries [22].

In developing the registry, the project coordinators followed EU guidance on the development of rare disease registries [23, 24]. The recommendations from the EU Committee of Experts on Rare Diseases (EUCERD) are shown in table 1, along with the mechanisms used by EMBARC to address these recommendations [23]. The EMBARC registry used a “hub and spoke” model to grow the registry across Europe, initially recruiting national experts or “champions” in individual countries who acted as the initial recruiting centres, and assisted with obtaining ethical/institutional review board approval and recruiting other centres in their respective countries, with the support of FIRS and the ERS national delegates. This was supplemented with e-mail invitations to participate through ERS Assembly 10 and publicity surrounding the launch of the registry at the ERS International Congress. This resulted in the recruitment of >150 centres in >40 countries (including both EU and non-EU countries) (figure 2). Importantly, EMBARC sought to establish a pan-European registry rather than merging existing datasets or national registries. By defining a core dataset that everyone in Europe shared, EMBARC avoided the problem of later having to achieve interoperability between different registries using different definitions on



Figure 2 Sites participating in the EMBARC registry as of January 2017.

different platforms. This may not be possible for all disease areas, where existing infrastructure in some countries may already exist.

The EMBARC registry

The EMBARC registry is managed from a data coordinating centre in the UK at the University of Dundee and received ethical approval in the UK in January 2015 (14/SS/1101). The study website is www.bronchiectasis.eu. A detailed protocol of the study has been published [18]. In brief, the inclusion criteria are a clinical history consistent with bronchiectasis (cough, chronic sputum production and/or recurrent respiratory infections) and computed tomography of the chest demonstrating bronchiectasis (bronchial dilatation) affecting one or more lobes. The exclusion criteria are bronchiectasis due to known cystic fibrosis, age <18 years and patients that are unable or unwilling to provide informed consent (figure 3). Patients are followed up on an annual basis with a detailed




Figure 3 The EMBARC registry flow chart. CT: computed tomography. Reproduced from [18].

Table 1 EUCERD recommendations for rare disease (RD) registries

Recommendation by EUCERD	EMBARC policy to address EUCERD recommendations
<p>1) RD patient registries and data collections need to be internationally interoperable as much as possible and the procedures to collect and exchange data need to be harmonised and consistent, to allow pooling of data when it is necessary to reach sufficient statistically significant numbers for clinical research and public health purposes.</p>	<p>EMBARC developed a case report form and registry software through an exhaustive consultation process with European stakeholders and aligning the fields where possible with colleagues in the USA bronchiectasis and NTM registry (https://clinicaltrials.gov/ct2/show/NCT01822834) [25].</p> <p>EMBARC has provided the registry software for free to researchers throughout Europe as well as well as the Australian, Indian and other non-EU bronchiectasis initiatives. By ensuring that all international bronchiectasis initiatives use the same case report form and core dataset, interoperability is ensured for future research and data exchange. Certain funders are now adopting a policy of only supporting registries that use the EMBARC platform.</p>
<p>2) All sources of data should be considered as sources of information for RD registries and data collections, to speed up the acquisition of knowledge and the development of clinical research.</p>	<p>EMBARC collects data directly from clinicians caring for patients with bronchiectasis. Data points have been determined by careful review by multiple stakeholders with a clear research and publication strategy determining the choice of variables.</p>
<p>2.1) As with all registries, registries for RDs should establish clear purposes and objectives of the data collection: the type of data collection should be suited to the need and the data captured should be appropriate to the proposed use of the data.</p>	<p>All centres of expertise in Europe for bronchiectasis were contacted and invited to participate in the registry. In countries without recognised expert centres, FIRS and ERS national delegates were used to identify expert or interested centres for participation.</p>
<p>2.2) RD centres of expertise, where they exist, should contribute to a registry.</p>	<p>Electronic health records from any sector of healthcare delivery are a valuable source for core data collection. Automatic data acquisition from these sources should be envisaged to ease the data collection process.</p>
<p>2.3) Collection of data on RDs should be delineated in the national RD plan/strategy.</p>	<p>This is outside the scope of EMBARC responsibilities.</p>
<p>2.4) A system to allow the collection of data directly reported by patients should be included along with systems for data reported by clinicians.</p>	<p>This was not part of the original EMBARC project but a platform for direct data entry by patients is being developed for launch in 2018.</p>
<p>3) Collected data should be utilised for public health and research purposes.</p>	<p>EMBARC registry data are collected for public health and research purposes. EMBARC data are made freely available for use in supporting policy development at local, regional, national and international levels, an example of which is contributing to recommendations in the 2017 ERS bronchiectasis guidelines. In addition, EMBARC data have been used for submission to regulatory authorities in respect of off-label drug use.</p>
<p>3.1) RD data collected should be used to support policy development at local, regional, national and international level.</p>	<p>EMBARC registry data are collected for public health and research purposes. EMBARC data are made freely available for use in supporting policy development at local, regional, national and international levels, an example of which is contributing to recommendations in the 2017 ERS bronchiectasis guidelines. In addition, EMBARC data have been used for submission to regulatory authorities in respect of off-label drug use.</p>
<p>3.2) RD data collected should, where possible, facilitate clinical and epidemiological research and the monitoring of care provision and therapeutic interventions, including off-label use of approved drugs and existing medications.</p>	<p>EMBARC registry data have been used to conduct feasibility studies for >10 multicentre and multinational clinical trials including academic and commercial studies.</p>
<p>3.3) RD data collected should, where possible, be used to provide information for multicentre and multinational clinical trial feasibility studies.</p>	<p>EMBARC registry data have been used to conduct feasibility studies for >10 multicentre and multinational clinical trials including academic and commercial studies.</p>

- 3.4) Pooling of data across data collections and other resources, including internationally, should be encouraged to reach a critical mass for data analysis. According to the governance/oversight criteria, data should be made accessible to groups with legitimate questions such as researchers and policy/decision makers.
- 3.5) Access and sharing of data should be defined to control how data is shared and published in the public domain.

4) Patient registries and data collections should adhere to good practice guidelines in the field. Specific to the current and future specificities of RD registries.

- 4.1) Involvement of stakeholders such as patients, policymakers, researchers and clinicians (and industry, where appropriate) in the design, analysis and governance of registries is important to address the complexity and scarcity of knowledge on RDs.
- 4.2) Representatives of all stakeholders should be invited to provide best possible expert support through an advisory board or committee to ensure appropriate information flow and knowledge exchange into and from the registry, and they should define a sustainability and exit strategy for the registry. Where appropriate, representatives from industry should also provide input.
- 4.3) This multi-stakeholder model for registry governance should apply not only at a national level but also at the European level and/or pan-European Platform repository of RD registries.

- 4.4) The process for consenting patients for participation in a RD registry should take into account the wider European and international context to ensure that patients are well informed of this dimension and the consent process is in line with the legal requirements at European and International level.
- 4.5) Patients already in a RD registry may be required to go through an additional consenting step to ensure compatibility with such systems.
- 4.6) RD registries should have a system to provide regular feedback to registered patients and their clinical teams, recognising their specific role in the success of registries in this field.

- 5) Existing and future patient registries and data collections should be adaptable to serve regulatory purposes, where required.**
- 6) Patient registries and data collections should be sustainable for the foreseeable timespan of the registries' utility.**

EMBARC has a clearly defined, open and accessible data sharing policy. This is discussed in greater detail at <https://www.bronchiectasis.eu/dataaccess>. Publications are strongly encouraged and are supported by a scientific committee.

The EMBARC registry is run on a day-to-day basis by a coordinating centre consisting of the chief investigator and registry coordinator. The governance includes an executive group and a steering committee for the registry, which includes all relevant stakeholders across Europe. The governance also includes a PAG supported by the European Lung Foundation. Although the governance of the EMBARC registry does not include industry, EMBARC regularly consults with industry to ensure that the EMBARC project meets the needs of industry.

EMBARC governance is pan-European.

Consent to the EMBARC registry across Europe uses standardised consent and information forms which make clear the European and international nature of the study. All documents are compliant with European law.

Not applicable in EMBARC.

Regular feedback to clinical teams is provided through monthly newsletters. Feedback to patients is achieved through a website and through regular updates to the PAG via the European Lung Foundation.

EMBARC works with regulators and industry to ensure that the registry is suitable for future pharmacovigilance and other regulatory purposes.

EMBARC is supported by the ERS, charities, industry and by a public-private partnership (the EU Innovative Medicines Initiative). EMBARC provides funding to centres participating in the registry to promote high quality and sustainable data collection.

Note that recommendations 1, 5 and 6 have been abbreviated for readability purposes. NTM: nontuberculous mycobacterium; PAG: patient advisory group.

review case report form [18]. To date, the registry has recruited >8000 patients in just over 2 years of recruitment.

Data access rules and governance

Involvement of all relevant stakeholders, and fair and open access to data is essential for the success of large-scale registries and studies. EMBARC has achieved this by involving key opinion leaders and experienced bronchiectasis researchers in a registry steering committee that has guided the project from 2014 to 2017 (<https://www.bronchiectasis.eu/steering-committee>), by maintaining an international advisory board that includes the leads for the key non-European registries and experts representing four continents (<https://www.bronchiectasis.eu/international-advisory-board>), and by having a transparent data access policy.

Patients contribute their time to participating in research, and contribute their data to a registry because they want to see the data used to improve clinical care and to bring forward advances in medical research. The EMBARC registry has therefore been developed with the principle that data should be as freely available as possible, and that the results of the study should be disseminated as widely as possible in order to have the greatest possible impact on health and patient care.

The process of applying for data access is simple. The data access application form can be downloaded from <https://www.bronchiectasis.eu/dataaccess>

Governance processes surrounding data management and access are fully compliant with the UK Data Protection Act 1998, and Data Protection Directive 95/46/EC of the European Parliament and of the Council (1995) (this will be updated when the new EU data protection regulations take effect) [18].

A scientific committee, consisting of up to seven academic members of the EMBARC network, review all data requests to ensure scientific quality, and to plan the most appropriate publication and dissemination plans for registry data.

A crucial component of a successful network is a transparent, democratic and open approach. All positions within EMBARC committees and working groups are elected. Decision making is transparent with consultation and voting among the relevant committees where required. An annual meeting of the whole EMBARC network is held at the ERS International Congress each year with more regular meetings of the executive and steering committees. All of the major contributing countries to EMBARC have a representative that forms part of the governance structure, ensuring that each contributing country has an equal voice in decision making.

Patient involvement

EMBARC works closely with the European Lung Foundation (ELF) (www.europeanlung.org), which was established by the ERS in 2000 with the aim of bringing together patients and the public with respiratory professionals to positively influence lung health. The design of the registry and all EMBARC activities have been informed by review and feedback from patients and patient groups [26, 27]. The ELF and EMBARC have ensured ongoing patient involvement in the network through the creation of a patient advisory group (PAG) consisting of people with bronchiectasis and those affected by bronchiectasis, such as parents, partners or children of someone with bronchiectasis. All EMBARC projects and meetings now involve patient representatives.

Achievements of EMBARC

The EMBARC registry represents a major achievement in the field of bronchiectasis given the lack of coordinated research activity prior to the commencement of the EMBARC study in 2015. The EMBARC protocol was published in 2016 and the first data publications from the EMBARC registry will be submitted for publication in mid- to late 2017 [18]. In addition to the registry, EMBARC has contributed to the field in a number of important ways since 2012 as described below.

Publications

EMBARC aligned 10 datasets from different European countries, which were collected by investigators prior to the start of the EMBARC registry in 2015 [28–34]. This approach of pooling existing datasets is commonly utilised in other diseases; for example, cystic fibrosis and primary ciliary dyskinesia [35, 36]. By standardising definitions, end-points and covariate data-points, a dataset of >2000 patients has been built for epidemiological studies. The dataset is designated FRIENDS (Facilitating Research Into Existing National Datasets) [28–34]. This cohort was used to derive and validate the first multicomponent clinical prediction tool for bronchiectasis, the bronchiectasis severity index (BSI) [37]. The study showed that a small number of key parameters were associated with mortality, hospital admissions, quality of life and future exacerbations [37]. Specifically, the BSI consists of age, functional status (Medical Research Council dyspnoea score), forced expiratory volume in 1 s (FEV₁), radiological severity (number of lobes involved or the presence of cystic dilatation), low body mass index (<18.5), frequency of exacerbations, history of hospitalisation for severe

exacerbations and the presence of chronic infection with bacteria or particularly with *Pseudomonas aeruginosa*. The resulting score is available at www.bronchiectasisseverity.com [37].

Subsequently, the BSI was compared to a second scoring system, the FACED score (FEV₁, age, chronic colonisation, extension and dyspnoea), for its ability to predict clinically relevant outcomes [29]. Both scores appear to perform equally well for the prediction of mortality across several cohorts but the EMBARC study of 1612 patients found that the BSI also predicted hospital admissions for severe exacerbations, moderate exacerbations, quality of life, respiratory symptoms, and even 6-min walk distance and lung function decline [29]. In contrast, the FACED score did not consistently predict any relevant clinical outcomes beyond mortality [29].

Collaborators from EMBARC have also published data demonstrating the characteristics of bronchiectasis in the elderly [30], demonstrating that only a minority of bronchiectasis patients are represented in current randomised clinical trials, such as those of inhaled antibiotics and mucoactive therapies [31].

A cluster analysis of different clinical characteristics performed by ALIBERTI *et al.* [32] identified four clusters of patients with different “phenotypes” and different outcomes. Bacteriology in sputum, defined by the presence of *P. aeruginosa* or other bacteria, were key drivers of clinical characteristics, while a third cohort was patients with daily sputum without chronic colonisation, and the final group were patients with dry bronchiectasis. Higher levels of neutrophilic inflammation were associated with the two bacterial colonisation phenotypes, consistent with prior literature [32].

Research priorities identified by the PSG have led directly to important EMBARC publications. The PAG overwhelmingly felt that comorbid conditions were often their most important determinants of quality of life. Based on their recommendation, the FRIENDS database was used to investigate the relative importance of comorbidities to disease outcomes in bronchiectasis. Standardised definitions of comorbidities were applied across the datasets to 986 patients with bronchiectasis. Patients had a median of four comorbidities per patient (with some patients having up to 20). 13 comorbidities were independently associated with mortality in multivariable analysis [28]. Although the individual contribution of each comorbidity was modest, multiple comorbidities that could be added together as part of an aetiology and comorbidity index (Bronchiectasis Aetiology and Comorbidity Index) predicted mortality and were associated with health-related quality of life as measured by the St George’s Respiratory Questionnaire. Patients with more comorbidities also had more exacerbations. The study confirmed the view of the PAG that multimorbidity is a major determinant of quality of life and outcomes in bronchiectasis [28].

Further work has defined the most common underlying causes of bronchiectasis in Europe, with 20% being classified as post-infective, 15% due to chronic obstructive pulmonary disease (COPD), 10% due to connective tissue diseases and 6% due to immunodeficiency [33]. 13% of cases led to a change in patients’ management [33]. De Soyza *et al.* [34] recently confirmed that patients with rheumatoid arthritis-associated bronchiectasis and COPD have worse clinical outcomes. EMBARC researchers have also recently identified a series of biomarkers associated with worse outcomes [38, 39].

A meta-analysis performed by EMBARC researchers identified that patients with *P. aeruginosa* infection are at three-fold increased risk of death and seven times more likely to be admitted to hospital for severe exacerbations [40].

Improving the quality of care for patients with bronchiectasis is also a major priority for the network. An audit conducted in Italy showed only 32% of patients had aetiological testing for allergic bronchopulmonary aspergillosis and immunodeficiency, with nearly 60% of patients having no aetiological testing [41]. Only 27% of patients had a sputum culture once per year. Compliance with other quality standards of care was similarly low. Improving standards of care across Europe is important and will be a major objective following the publication of the 2017 ERS guidelines [41].

World Bronchiectasis Conference

EMBARC held the first international conference specifically focussed on bronchiectasis in 2016 in Hannover, Germany. The meeting was attended by nearly 300 delegates and was a great success both in terms of the scientific content and also in raising the profile of bronchiectasis. The second EMBARC World Bronchiectasis Conference was held in Milan, Italy in July 2017 and the third is scheduled for Washington, DC, USA, in 2018.

Consensus statements

Expert networks like EMBARC can provide important guidance to the field by producing consensus statements. The first such document was published by EMBARC in 2016 describing the research priorities for the field: the European Bronchiectasis Research Roadmap [19]. A Delphi process was conducted identifying the research priorities of a Europe-wide group of experts in bronchiectasis. This was complemented by a survey of nearly 1000 patients and carers to produce a physician/patient consensus of research priorities. 22 research questions and 55 different studies were proposed, emphasising the volume of work there is to be done [19] (table 2).

Table 2 Selected translational research priorities from the EMBARC roadmap [19]

Key translational research questions	Recommendations
What causes bronchiectasis?	DNA biobanks linked to well-phenotyped patient cohorts should be established to enable underlying genetic susceptibility to bronchiectasis to be established.
What causes bronchiectasis exacerbations?	A comprehensive study enrolling patients when stable and during exacerbation should be conducted, evaluating the impact of bacteria, viruses, fungi and noninfectious stimuli to identify the cause(s) of bronchiectasis exacerbations.
Development of new therapies and biomarkers	A deeper understanding of the inflammatory pathways in bronchiectasis is needed to develop new therapies. We recommend using emerging techniques and technologies (particularly proteomics, metabolomics and genomics) in large, well-characterised cohorts to identify new treatment targets and deeper patient phenotyping.
How does the microbiome impact patient outcomes in bronchiectasis?	We suggest studies of the microbiome (incorporating bacteria and potentially fungi) in bronchiectasis linked to detailed clinical phenotyping data.
Why do some patients become infected with <i>Pseudomonas aeruginosa</i>?	Mechanistic studies investigating the genetic, microbiological, inflammatory and clinical susceptibility factors for <i>P. aeruginosa</i> colonisation should be conducted.

Exacerbations are the key clinical end-point in randomised controlled trials of bronchiectasis but all studies to date have used slightly different definitions of exacerbation [42–46]. This can have a major effect on the results of trials: too stringent a definition can result in missing a signal for benefit while too loose a definition can result in normal day-to-day variation in symptoms or side-effects from medications being classified as exacerbations. This can dilute a signal for benefit.

To address this, members of EMBARC led a consensus working group at the World Bronchiectasis Conference in Hannover, in collaboration with colleagues from the USA, Australia, South Africa and New Zealand [47]. A Delphi process identified the key symptoms and signs of exacerbation as determined by expert opinion, and a resulting simple and operational definition of exacerbation was approved and published (figure 4). It should be noted this definition is for use in clinical trials and is not intended to impact clinical care [47].

Such consensus statements, while based on expert opinion, can have an important impact on the field. Further consensus documents are planned in 2017 and beyond.

International bronchiectasis networks

In addition to supporting European research, EMBARC has made the dataset and platform available for international collaborators to use. Alignment with other international initiatives is a key EUCERD recommendation for registries, and allows integrated analysis and higher impact outputs. Two excellent examples of partnered international networks are the Australian and Indian registries.

The Australian registry is an initiative of the Lung Foundation of Australia. It collects the “core” dataset using the EMBARC platform allowing collaborative analyses but also incorporates unique




Figure 4 Consensus definition of bronchiectasis exacerbations for use in clinical trials. #: physicians should exclude other possible causes of deterioration in symptoms. Reproduced and modified from [47].

Australian features, such as a paediatric component and data fields related to indigenous Australians, among others [48, 49]. This demonstrates the value of having a core dataset while permitting the flexibility to explore local strengths and key research questions at a local level. The Indian registry (EMBARC-India) is further example of this. Coordinated by the Respiratory Research Network of India and collecting data across 25 sites, this dataset represents the first attempt to understand the impact of bronchiectasis in south-east Asia where virtually no data have been published. The first results were presented at the American Thoracic Society Conference in 2017, with 680 patients reported. In contrast to European cohorts, the majority of patients were male (60%) and post-tuberculosis was the most frequent underlying cause (35.7%) [50].

More and more countries are developing bronchiectasis research infrastructure using the EMBARC platform as a basis for ensuring interoperability and future intercontinental research.

Randomised controlled trials

EMBARC ultimately wishes to facilitate and support randomised controlled trials within its network. At the time of writing, EMBARC is actively supporting three randomised controlled trials of new therapies for bronchiectasis. The registry provides a powerful tool for planning and executing trials, by allowing feasibility studies to determine how changes in protocol design may impact recruitment, and by identifying which sites are most likely to contribute to trials and can be used to actively encourage investigators to take part in trials. The registry and EMBARC network can also provide patient input into trial design as well as facilitating expert review.

EMBARC is part of the iABC (Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis) consortium, an EU Innovative Medicines Initiative consortium that includes a programme to develop tobramycin dry powder for inhalation [51]. A phase 2 study is currently enrolling in Europe for bronchiectasis patients with *P. aeruginosa* infection.

The future: EMBARC 2

The registry and the associated projects described above represent important achievements for a previously neglected disease [52–55]. Nevertheless, the European Bronchiectasis Roadmap identified a series of priorities for research, only around half of which can be answered by epidemiological studies such as registries. In renewing the EMBARC project from 2017 to 2020, EMBARC has developed ambitious plans to expand its activities.

There has been little translational research into bronchiectasis and its pathophysiology remains largely unexplored. From 2017 to 2020, EMBARC

Educational questions

- Which of the following statements regarding the EUCERD recommendations for rare disease registries is correct?
 - To ensure data quality, data entry to registries should always be performed by trained healthcare professionals and not directly by patients
 - Data quality in routine or electronic healthcare records is typically poor, and should not be integrated with registry data
 - Registries should be made available to perform feasibility studies for randomised controlled trials
 - European centres of excellence for rare or complex diseases do not have a responsibility to contribute to registries
 - Pooled analysis of data with registries outside of Europe is not permitted by data protection regulations
- Which of the following statements regarding registry governance are correct?
 - There are no specific European/EU data protection requirements and so processes should be determined by requirements at national level on a case-by-case basis.
 - It is easier and more efficient to establish individual registries at national levels and then develop algorithms to integrate datasets than it is to have a single pan-European database
 - Centres participating in registries generally do not require funding for this activity
 - EUCERD guidelines suggest that industry should never be involved in registry governance
 - Data access procedures should be simple, and ensure that all relevant stakeholders can access data where it is in the public interest
- Which of the following features have not been identified as determinants of bronchiectasis severity in EMBARC studies?
 - Post-infective aetiology
 - A history of rheumatoid arthritis
 - A history of three or more exacerbations per year
 - Chronic infection with *P. aeruginosa*
 - Low FEV₁
- Which of the following statements regarding bronchiectasis registries internationally is not correct?
 - Pulmonary tuberculosis is an important underlying cause of bronchiectasis in India
 - Pulmonary NTM were isolated in >30% of patients in the USA bronchiectasis registry
 - The Australian registry incorporates data on indigenous Australians as this group has a high prevalence of bronchiectasis
 - COPD is a rarely reported comorbidity (<5%) in European patients with bronchiectasis
 - The finding that comorbidities predict mortality in the EMBARC dataset is likely to be a unique finding to Europe

will expand an international bioresource, using the registry as a backbone to build a repository of blood, DNA, sputum and other biological materials for use in translational research. This study will allow detailed studies on airway and

Suggested answers

- 1 c. A key role of registries is to facilitate randomised controlled trials. EUCERD recommends that registries should establish methods to perform feasibility studies for randomised controlled trials.
- 2 e. EUCERD and other's guidance related to registries emphasise the importance of making data available and disseminating results. Patients provide their data to the registry with the understanding it will be used for research and to improve clinical care. This mandates simple and open approaches to data sharing. There are specific EU data protection regulations that apply throughout the EU and must be followed for EU projects. It is highly complex and challenging to integrate different datasets compared to having a single core dataset with unified procedures. Again, this is a recommendation of EUCERD. Finally, industry involvement may be entirely relevant and appropriate for some registry projects and not appropriate for others, but EUCERD guidelines certainly do not forbid industry involvement in registries.
- 3 a. No evidence of long-term prognostic benefit or harm associated with post-infective aetiology has been reported. In contrast, all of the other four factors have been reported to be associated with higher mortality, increased rates of hospital admission or other adverse outcomes.
- 4 d. COPD is reported relatively frequently in European studies (10–50%) and in the most recent EMBARC data reports is reported in 15–20% of cases. It is also commonly reported in the USA and in all other territories where bronchiectasis data are available.

systemic inflammation, microbiota and genomics to answer fundamental questions regarding pathophysiology [56–61].

The overlap between COPD, asthma and bronchiectasis is a key priority in the field, and will be explored in new clinical and translational studies within the network [6]. Furthermore, there are very few data published on the presentation and

outcomes of patients with bronchiectasis during exacerbation. EMBARC has initiated an exacerbation study where patients are enrolled at the onset of exacerbation with detailed data collection and longitudinal follow-up in the registry. This will allow a deeper understanding of presentation and outcomes of bronchiectasis exacerbations.

Nontuberculous mycobacterial (NTM) disease represents a major healthcare problem linked to bronchiectasis [62]. >50% of patients in the US bronchiectasis registry have co-existing NTM disease, whereas the rate is much lower in Europe [25]. Since NTM patients require different management to those with bronchiectasis without NTM, EMBARC will launch a specific registry for NTM, with new data fields and a separate governance structure, in 2017 to capture and study in greater detail this important patient group.

The development of EMBARC from 2017 to 2020 illustrates what is possible with the support of a successful registry and with the support of a group of highly motivated international experts.

Conclusion

EMBARC is a successful ERS CRC. The major factors in its success are a clear set of objectives, engagement from the overwhelming majority of experts and stakeholders in the field, a highly professional organisational infrastructure, and dedicated cooperative members who have a unifying goal of improving patient care.

EMBARC has already made an important contribution to bronchiectasis research and guidelines. Developments in the next 3 years should result in an even greater impact, with contributions to epidemiology, translational research, advocacy, education and clinical trials.

Conflict of interest

J. Boyd is an employee of the European Lung Foundation. All other disclosures can be found alongside this article at breathe.ersjournals.com

References

1. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. *Eur Respir J* 2015; 45: 1446–1462.
2. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. *Mol Immunol* 2013; 55: 27–34.
3. Khoo JK, Venning V, Wong C, *et al.* Bronchiectasis in the last five years: new developments. *J Clin Med* 2016; 5: E115.
4. Dudgeon E, Crichton M, Chalmers JD. The missing ingredient: the patient perspective of health related quality of life in bronchiectasis: a qualitative study. *BMC Pulm Med* 2017 in press.
5. Chalmers JD, Sethi S. Raising awareness of bronchiectasis in primary care; overview of diagnosis and management strategies in adults. *NPJ Prim Care Respir Med* 2017; 27: 18.
6. Hurst JR, Elborn JS, De Soyza A. COPD–bronchiectasis overlap syndrome. *Eur Respir J* 2015; 45: 310–313.
7. Quint JK, Millett ERC, Joshi M, *et al.* Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. *Eur Respir J* 2016; 47: 186–193.
8. Monteagudo M, Rodríguez-Blanco T, Barrecheguren M, *et al.* Prevalence and incidence of bronchiectasis in Catalonia, Spain: a population based study. *Respir Med* 2016; 121: 26–31.
9. Ringshausen FC, de Roux A, Diel R, *et al.* Bronchiectasis in Germany: a population-based estimation of disease prevalence. *Eur Respir J* 2015; 46: 1805–1807.
10. Goeminne PC, De Soyza A. Bronchiectasis: how to be an orphan with many parents? *Eur Respir J* 2016; 47: 10–13.
11. Mandal P, Chalmers JD, Graham C, *et al.* Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. *Lancet Respir Med* 2014; 2: 455–463.

12. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. *Thorax* 2010; 65: Suppl. 1, i1-58.
13. Chalmers JD, Elborn JS. Reclaiming the name "bronchiectasis". *Thorax* 2015; 70: 399-400.
14. Vendrell M, de Gracia J, Oliveira C, et al. Diagnóstico y tratamiento de las bronquiectasias. SEPAR. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery.] *Arch Bronconeumol* 2008; 44: 629-640.
15. Rosen MJ. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. *Chest*. 2006; 129: Suppl., 122S-131S.
16. O'Donnell AE, Barker AF, Ilowite JS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rDNase study group. *Chest* 1998; 113: 1329-1334.
17. Aliberti S. Presented at European Respiratory Society 2015.
18. Chalmers JD, Aliberti S, Polverino E, et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. *ERJ Open Res* 2016; 2: 00081-2015.
19. Aliberti S, Masfield S, Polverino E, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. *Eur Respir J* 2016; 48: 632-647.
20. European Respiratory Society. Clinical Research Collaborations. www.ersnet.org/research/clinical-research-collaborations Date last accessed: May 28, 2017.
21. Djukanovic R, Bruselle G, Walker S, et al. The era of research collaborations: new models for working together. *Eur Respir J* 2017; 49: 1601848.
22. Oliveira C, Padilla A, Martínez-García MÁ, et al. Etiology of bronchiectasis in a cohort of 2047 patients: an analysis of the Spanish historical bronchiectasis registry. *Arch Bronconeumol* 2017; 53: 366-374.
23. European Union Committee of Experts on Rare Diseases. EUCERD Core Recommendations on Rare Disease Patient Registration and Data Collection. www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_RDRegistryDataCollection_adopted.pdf Date last accessed: May 28, 2017. Date last updated: June 5, 2013.
24. European Union Committee of Experts on Rare Diseases. Minimum Data Set for Rare Disease Registries. www.eucerd.eu/wp-content/uploads/2015/03/WP8_Registries_MDS.pdf Date last accessed: May 28, 2017. Date last updated: January 2015.
25. Aksamit TR, O'Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. *Chest* 2017; 151: 982-992.
26. Supple D, Roberts A, Hudson V, et al. From tokenism to meaningful engagement: best practices in patient involvement in an EU project. *Res Involvement Engagement* 2015; 1: 5.
27. Powell P, Williams S, Smyth D. European Lung Foundation: from local to global. *Breathe* 2016; 12: 236-242.
28. McDonnell MJ, Aliberti S, Goeminne PC, et al. Co-morbidities and the risk of mortality in patients with bronchiectasis. An international cohort study. *Lancet Respir Med* 2016; 4: 969-979.
29. McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis-analysis of 7 European Cohorts. *Thorax* 2016; 71: 1110-1118.
30. Bellelli G, Chalmers JD, Sotgiu G, et al. Characterization of bronchiectasis in the elderly. *Respir Med* 2016; 119: 13-19.
31. Chalmers JD, McDonnell MJ, Rutherford R, et al. The generalizability of bronchiectasis randomized controlled trials: a multicentre cohort study. *Respir Med* 2016; 112: 51-58.
32. Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. *Eur Respir J* 2016; 47: 1113-1122.
33. Lonni S, Chalmers JD, Goeminne PC, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its relationship to severity. *Ann Am Thorac Soc* 2015; 12: 1764-1770.
34. De Soya A, McDonnell MJ, Goeminne PC, et al. Bronchiectasis Rheumatoid overlap syndrome (BROS) is an independent risk factor for mortality in patients with bronchiectasis: A multicentre cohort study. *Chest* 2017; 151: 1247-1254.
35. McCormick J, Mehta G, Olesen HV, et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. *Lancet* 2010; 375: 1007-1013.
36. Goutaki M, Maurer E, Halbeisen FS, et al. The international primary ciliary dyskinesia cohort (iPCD cohort): methods and first results. *Eur Respir J* 2017; 49: 1601181.
37. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index: an international derivation and validation study. *Am J Respir Crit Care Med* 2014; 189: 576-585.
38. Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, et al. Secreted mucins and airway bacterial colonization in non-CF bronchiectasis. *Respirology* 2016; 20: 1082-1088.
39. Chalmers JD, Moffitt KL, Suarez-Cuartin G, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. *Am J Respir Crit Care Med* 2017; 195: 1384-1393.
40. Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of *Pseudomonas aeruginosa* colonisation on prognosis in adult bronchiectasis. *Ann Am Thorac Soc* 2015; 12: 1602-1611.
41. Aliberti S, Hill AT, Mantero M, et al. Quality standards for the management of bronchiectasis in Italy: a national audit. *Eur Respir J* 2016; 48: 244-248.
42. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. *Lancet* 2012; 380: 660-667.
43. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials. *Lancet Respir Med* 2014; 2: 738-749.
44. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic *Pseudomonas aeruginosa* infection. *Am J Respir Crit Care Med* 2014; 189: 975-982.
45. Altenburg J. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. *JAMA* 2013; 309: 1251-1259.
46. De Soya A, Pavord I, Elborn JS, et al. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. *Eur Respir J* 2015; 1021-1032.
47. Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. *Eur Respir J* 2017; 49: 170051.
48. Redding GJ, Singleton RJ, Valery PC, et al. Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. *Chest* 2014; 146: 762-774.
49. Visser S, Allan H, Burr L, et al. The Australasian Bronchiectasis Registry - early steps in mapping the impact of bronchiectasis in Australia and New Zealand. *Am J Respir Crit Care Med* 2017; 195: A4723.
50. Dhar R, Mohan M, D'souza G, et al. Phenotype characterization of non cystic fibrosis bronchiectasis in India: baseline data from an Indian Bronchiectasis Registry. *Am J Respir Crit Care Med* 2017; 195: A4726.
51. Kostyanov T, Bonten MJ, O'Brien S, et al. The Innovative Medicines Initiative New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. *J Antimicrob Chemother* 2016; 71: 290-295.
52. Suarez-Cuartin G, Chalmers JD, Sibila O. Diagnostic challenges of bronchiectasis. *Respir Med* 2016; 116: 70-77.
53. Chalmers JD, Loebinger M, Aliberti S. Challenges in the development of new therapies for bronchiectasis. *Curr Opin Pharmacother* 2015; 16: 833-850.
54. Blasi F, Chalmers JD, Aliberti S. COPD and bronchiectasis: phenotype, endotype or co-morbidity? *COPD* 2014; 11: 603-604.
55. Redondo M, Keyt H, Dhar R, et al. Bronchiectasis and cystic fibrosis: global impact. *Breathe* 2016; 12: 222-235.

56. Chalmers JD, McHugh BJ, Doherty CJ, *et al.* Mannose binding lectin deficiency and disease severity in non-CF bronchiectasis: a prospective study. *Lancet Respir Med* 2013; 1: 175-274.
57. Szymanski EP, Leung JM, Fowler CJ, *et al.* Pulmonary nontuberculous mycobacterial infection. A multisystem, multigenic disease. *Am J Respir Crit Care Med* 2015; 192: 618-628.
58. Tunney MM, Einarsson GG, Wei L, *et al.* Lung Microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. *Am J Respir Crit Care Med* 2013; 187: 1118-1126.
59. Rogers GB, Bruce KD, Martin ML, *et al.* The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. *Lancet Respir Med* 2014; 2: 988-996.
60. Dicker AJ, Crichton ML, Pumphrey EG, *et al.* Neutrophil extracellular traps link disease severity and bacterial diversity in COPD via impaired phagocytosis. *J Allergy Clin Immunol* 2017 [in press <https://doi.org/10.1016/j.jaci.2017.04.022>].
61. Goeminne PC, Vandooren J, Moelants EA, *et al.* The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. *Respirology* 2014; 19: 203-210.
62. Faverio P, Stainer A, Bonaiti G, *et al.* Characterizing non-tuberculous mycobacteria infection in bronchiectasis. *Int J Mol Sci* 2016; 17: E1913.